REMARKS/ARGUMENTS

Applicants hereby elects without traverse to prosecute in this application the subject matter of Group XI, drawn to a single exon nucleic acids microarray wherein at least 50% of the probes include genomic sequence, classified in class 435, subclass 287.2. Applicants reserve the right to prosecute any subject matter not examined here in one or more divisional application(s).

Claims 1 - 92 are pending. Applicants herein withdraw without prejudice claims 15 - 60 and 82 - 92, and cancel without prejudice claims 1 - 14. Applicants amend claim 81 to correct an error. Applicants add new claims 93 - 104, which fall within the restriction group elected for prosecution on the merits. Support for the claims newly added and amended may be found throughout the specification, including the claims as originally filed. No new matter has been added.

Applicants enclose herewith an Amendment Transmittal Letter authorizing the payment of the fee for the new claims to be debited from Applicants' Deposit Account. A copy for charging purposes is enclosed as well.

Appl. No. 09/774,203 Amendment dated November 6, 2003 Reply to Office action of October 6, 2003

Additionally, enclosed is a copy of an Associate Power of Attorney.

Early and favorable action is earnestly solicited.

Respectfully submitted,

AMERSHAM BIOSCIENCES CORP

Registration No.: 53,073

Amersham Biosciences Corp 800 Centennial Avenue P. O. Box 1327 Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875 Fax: (732) 457-8463

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on November 6, 2003.

Signature:

Name:

Melissa Leck